Author

P. Troncoso

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

C. J. Logothetis· 3 shared J. Zhang· 2 shared X. Song· 2 shared A. Aparicio· 1 shared A. Futreal· 1 shared A. G. Hoang· 1 shared A. K. Ghosh· 1 shared A. K. Jain· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. J. Logothetis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Integrative analysis of the MD Anderson Prostate Cancer Patient-Derived Xenograft Series (MDA PCa PDX)

N. Anselmino, E. Labanca, X. Song, J. Yang, P. D. Shepherd, J. Dong, R. Kundra, N. Schultz, J. Zhang, J. C. Araujo, A. M. Aparicio, S. K. Subudhi, P. G. Corn, L. L. Pisters, J. F. Ward, , N. M. Navone

The paper characterizes the genomic and transcriptomic landscape of MDA PCa PDX models and develops an organoid platform to study prostate cancer heterogeneity and resistance.

bioRxiv · Jul 21, 2022 · PreprintCancer Biology

KDM4A promotes the progression of neuroendocrine prostate cancer

C. S. L. Mak, M. Zhu, X. Liang, F. Wang, F. Yuan, A. G. Hoang, X. Song, P. Shepherd, D. Liang, J. Suh, B. Pradhan, J. Park, M. Zhang, E. Metzger, R. Schule, , G. Wang

This study identifies KDM4A as a key driver of neuroendocrine prostate cancer progression and shows that targeting KDM4A inhibits tumor growth in preclinical models.

bioRxiv · May 14, 2022 · PreprintCancer Biology

H3K4me1-marked Enhancer Activation in Resistant Prostate Cancers Implicates SOX4 and MENIN Inhibition as Therapeutic Strategies

C. Terranova, M. Maitituoheti, A. T. Raman, M. Tang, N. E. Anvar, A. K. Ghosh, S. B. Amin, J. Schulz, E. Orouji, F. Giancotti, P. Troncoso, C. J. Logothetis, T. Thompson, K. Rai

The paper identifies H3K4me1-marked enhancers in therapy-resistant prostate cancers and suggests SOX4 and MENIN inhibition as therapeutic strategies.

bioRxiv · Sep 2, 2021 · PreprintCancer Biology